[go: up one dir, main page]

PE20081377A1 - Compuestos de tiazol pirazolopirimidina - Google Patents

Compuestos de tiazol pirazolopirimidina

Info

Publication number
PE20081377A1
PE20081377A1 PE2007001271A PE2007001271A PE20081377A1 PE 20081377 A1 PE20081377 A1 PE 20081377A1 PE 2007001271 A PE2007001271 A PE 2007001271A PE 2007001271 A PE2007001271 A PE 2007001271A PE 20081377 A1 PE20081377 A1 PE 20081377A1
Authority
PE
Peru
Prior art keywords
thiazol
propyl
ethyl
compounds
disorders
Prior art date
Application number
PE2007001271A
Other languages
English (en)
Inventor
Zhaogen Chen
Erik James Hembre
Philip Arthur Hipskind
Takako Takakuwa
James Lee Toth
Hamdouchi Chafiq Hamdouchi
Jason Kenneth Myers
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081377(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20081377A1 publication Critical patent/PE20081377A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TIAZOL PIRAZOLOPIRIMIDINA DE FORMULA (I), EN DONDE R1 Y R2 SON INDEPENDIENTEMENTE ETILO O n-PROPILO; R3 ES H, Cl, Br, METILO, TRIFLUOROMETILO O METOXI; R4 ES H, Br, RaRbN-, METOXIMETILO, PIRIDIN-4-ILO, MORFOLIN-4-ILO, ENTRE OTROS. SON SELECCIONADOS: 7-(1-ETIL-PROPIL)-2,5-DIMETIL-3-(4-METIL-TIAZOL-5-IL)-PIRAZOLO[1,5-a]PIRIMIDINA, 3-(2,4-DIBROMO-TIAZOL-5-IL)-7-(1-ETIL-PROPIL)-2,5-DIMETIL-PIRAZOLO[1,5-a]PIRIMIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR CRF1 (FACTOR DE LIBERACION DE CORTICOTROPINA), POR LO QUE SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS, TRASTORNOS PSIQUIATRICOS, NEUROENDOCRINOS, TRASTORNOS NEUROLOGICOS Y SINDROME METABOLICO
PE2007001271A 2006-09-20 2007-09-20 Compuestos de tiazol pirazolopirimidina PE20081377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82626406P 2006-09-20 2006-09-20

Publications (1)

Publication Number Publication Date
PE20081377A1 true PE20081377A1 (es) 2008-09-18

Family

ID=38924802

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001271A PE20081377A1 (es) 2006-09-20 2007-09-20 Compuestos de tiazol pirazolopirimidina

Country Status (33)

Country Link
US (1) US8030304B2 (es)
EP (1) EP2094709B1 (es)
JP (1) JP5161226B2 (es)
KR (1) KR101088239B1 (es)
CN (1) CN101516887B (es)
AR (1) AR062886A1 (es)
AT (1) ATE481405T1 (es)
AU (1) AU2007297421B2 (es)
BR (1) BRPI0717023B8 (es)
CA (1) CA2663511C (es)
CL (1) CL2007002693A1 (es)
CR (1) CR10682A (es)
CY (1) CY1110854T1 (es)
DE (1) DE602007009305D1 (es)
DK (1) DK2094709T3 (es)
EA (1) EA015179B1 (es)
ES (1) ES2350282T3 (es)
HR (1) HRP20100516T1 (es)
IL (1) IL197614A (es)
MA (1) MA30798B1 (es)
MX (1) MX2009003125A (es)
MY (1) MY146388A (es)
NO (1) NO20091489L (es)
NZ (1) NZ575572A (es)
PE (1) PE20081377A1 (es)
PL (1) PL2094709T3 (es)
PT (1) PT2094709E (es)
RS (1) RS51545B (es)
SI (1) SI2094709T1 (es)
TN (1) TN2009000095A1 (es)
TW (1) TWI402269B (es)
UA (1) UA96458C2 (es)
WO (1) WO2008036579A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010039678A1 (en) * 2008-10-02 2010-04-08 Eli Lilly And Company Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20170020877A1 (en) 2014-01-21 2017-01-26 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CN109906222B (zh) 2016-09-07 2023-08-01 加利福尼亚大学董事会 减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂
CN110996943A (zh) 2017-08-14 2020-04-10 云杉生物科学公司 促肾上腺皮质激素释放因子受体拮抗剂
WO2019036472A1 (en) * 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
CA3098562A1 (en) 2018-04-27 2019-10-31 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
WO2020115555A2 (en) 2018-12-07 2020-06-11 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
MX2022000812A (es) * 2019-07-19 2022-02-16 Spruce Biosciences Inc Metodos de tratamiento de hiperplasia suprarrenal congenita.
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
ES3039926T3 (en) * 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
CA3188730A1 (en) * 2020-08-12 2022-02-17 Christopher Barnes Methods and compositions for treating polycystic ovary syndrome
EP4203964A1 (en) 2020-08-26 2023-07-05 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
CA3211644A1 (en) 2021-03-19 2022-09-22 Christine FERRARA-COOK Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
EP4402142A4 (en) * 2021-11-19 2025-07-23 Spruce Biosciences Inc CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (en) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome
WO2025188842A1 (en) * 2024-03-08 2025-09-12 Spruce Biosciences, Inc. Amorphous solid dispersion of tildacerfont formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0674641T3 (da) 1992-12-17 1999-09-27 Pfizer Pyrrolopyrimidiner som CRF-antagonister
NZ330119A (en) * 1996-02-07 2000-02-28 Janssen Pharmaceutica Nv Pyrazolopyrimidines as crf receptor antagonists
WO1998003510A1 (en) * 1996-07-24 1998-01-29 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
CN1104432C (zh) * 1996-07-24 2003-04-02 杜邦药品公司 吡咯并三嗪和嘧啶化合物
EP0923582B1 (en) 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
HUP0203131A3 (en) * 1999-09-30 2004-06-28 Pfizer Amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use
DE60218434T2 (de) * 2001-03-13 2007-11-08 Bristol-Myers Squibb Pharma Co. 4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-Aö-1,3,5-TRIAZIN, SEINE ENANTIOMEREN UND PHARMAZEUTISCH ANNEHMBARE SALZE ALS CORTICOTROPIN-RELEASING-FACTOR-REZEPTOR-LIGANDEN
AR046967A1 (es) 2003-12-22 2006-01-04 Sb Pharmco Inc Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion

Also Published As

Publication number Publication date
EA200970303A1 (ru) 2009-10-30
MX2009003125A (es) 2009-05-28
HRP20100516T1 (hr) 2010-10-31
IL197614A0 (en) 2009-12-24
US8030304B2 (en) 2011-10-04
AU2007297421B2 (en) 2012-03-08
EP2094709B1 (en) 2010-09-15
BRPI0717023B8 (pt) 2021-05-25
DK2094709T3 (da) 2010-12-06
BRPI0717023A2 (pt) 2014-03-11
TW200821312A (en) 2008-05-16
BRPI0717023B1 (pt) 2019-11-19
CN101516887B (zh) 2011-11-02
TN2009000095A1 (en) 2010-08-19
CA2663511C (en) 2012-12-04
CR10682A (es) 2009-08-13
CY1110854T1 (el) 2015-06-10
NZ575572A (en) 2011-10-28
DE602007009305D1 (de) 2010-10-28
JP5161226B2 (ja) 2013-03-13
KR20090052366A (ko) 2009-05-25
EA015179B1 (ru) 2011-06-30
IL197614A (en) 2012-10-31
CA2663511A1 (en) 2008-03-27
CL2007002693A1 (es) 2008-04-18
SI2094709T1 (sl) 2011-01-31
EP2094709A1 (en) 2009-09-02
TWI402269B (zh) 2013-07-21
ES2350282T3 (es) 2011-01-20
RS51545B (sr) 2011-06-30
MA30798B1 (fr) 2009-10-01
US20100222339A1 (en) 2010-09-02
MY146388A (en) 2012-08-15
JP2010504344A (ja) 2010-02-12
UA96458C2 (ru) 2011-11-10
AU2007297421A1 (en) 2008-03-27
CN101516887A (zh) 2009-08-26
PL2094709T3 (pl) 2011-02-28
HK1132505A1 (en) 2010-02-26
ATE481405T1 (de) 2010-10-15
KR101088239B1 (ko) 2011-11-30
PT2094709E (pt) 2010-10-04
AR062886A1 (es) 2008-12-10
NO20091489L (no) 2009-04-16
WO2008036579A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
PE20081377A1 (es) Compuestos de tiazol pirazolopirimidina
CR9389A (es) Compuestos de imidazopiridazina
ES2299896T3 (es) Derivados de benzazepina como antagonistas h3 de histamina.
EA200801000A1 (ru) Производные пиразоло[1,5-альфа]пиримидила, полезные в качестве антагонистов рецептора рилизинг-фактора кортикотропина (crf)
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
IL210071A (en) Derivatives of {3– (pyrid – 2 – illmethyl) –3 h– [1, 2, 3] triazolo [4, 5 – d] pyrimidine-5-amine}, their pharmaceutical preparations and their use in drug preparation
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
PE20070093A1 (es) Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c
CR9622A (es) Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3
EA200800992A1 (ru) 2-амино-7,8-дигидро-6н-пиридо[4,3-d]пиримидин-5-оны, способ их получения, способ терапии с их помощью, компонент композиции и композиция на их основе, 2,4-диоксопиперидиновые соединения для их получения
PL1620425T3 (pl) Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
EA200500172A1 (ru) Азабициклопроизводные в качестве антагонистов мускариновых рецепторов
PE20061318A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
MX2008011576A (es) Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
EA200600688A1 (ru) Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а
EA200501594A1 (ru) Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора
WO2004093789A3 (en) Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
WO2006114666A8 (en) SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES
MXPA06000774A (es) E3-nitro-pirazolo[1,5-a]pirimidinas 7-sustituidas y composiciones y metodos relacionados.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed